image
Healthcare - Medical - Instruments & Supplies - NASDAQ - US
$ 67.91
1.12 %
$ 15.1 B
Market Cap
28.18
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Aug, 5, 2025.

The intrinsic value of one HOLX stock under the worst case scenario is HIDDEN Compared to the current market price of 67.9 USD, Hologic, Inc. is HIDDEN

This DCF valuation model was last updated on Aug, 5, 2025.

The intrinsic value of one HOLX stock under the base case scenario is HIDDEN Compared to the current market price of 67.9 USD, Hologic, Inc. is HIDDEN

This DCF valuation model was last updated on Aug, 5, 2025.

The intrinsic value of one HOLX stock under the best case scenario is HIDDEN Compared to the current market price of 67.9 USD, Hologic, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart HOLX

image
$68.0$68.0$66.0$66.0$64.0$64.0$62.0$62.0$60.0$60.0$58.0$58.0$56.0$56.0$54.0$54.0$52.0$52.015 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '2515 Jul15 JulAug '25Aug '25
FINANCIALS
4.03 B REVENUE
-0.00%
970 M OPERATING INCOME
45.15%
790 M NET INCOME
73.14%
1.29 B OPERATING CASH FLOW
22.26%
-781 M INVESTING CASH FLOW
-413.48%
-1.11 B FINANCING CASH FLOW
-129.43%
0 REVENUE
0.00%
255 M OPERATING INCOME
3737.14%
195 M NET INCOME
1220.11%
343 M OPERATING CASH FLOW
102.66%
-4.3 M INVESTING CASH FLOW
98.67%
-40.1 M FINANCING CASH FLOW
80.12%
Balance Sheet Hologic, Inc.
image
Current Assets 3.82 B
Cash & Short-Term Investments 2.33 B
Receivables 600 M
Other Current Assets 889 M
Non-Current Assets 5.33 B
Long-Term Investments 151 M
PP&E 630 M
Other Non-Current Assets 4.55 B
25.49 %6.56 %9.71 %6.88 %49.72 %Total Assets$9.2b
Current Liabilities 1.04 B
Accounts Payable 204 M
Short-Term Debt 64.8 M
Other Current Liabilities 769 M
Non-Current Liabilities 2.99 B
Long-Term Debt 2.59 B
Other Non-Current Liabilities 396 M
5.06 %19.09 %64.41 %9.83 %Total Liabilities$4.0b
EFFICIENCY
Earnings Waterfall Hologic, Inc.
image
Revenue 4.03 B
Cost Of Revenue 1.8 B
Gross Profit 2.23 B
Operating Expenses 1.35 B
Operating Income 970 M
Other Expenses 181 M
Net Income 790 M
5b5b4b4b4b4b3b3b3b3b2b2b2b2b1b1b500m500m004b(2b)2b(1b)970m(181m)790mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
55.28% GROSS MARGIN
55.28%
24.07% OPERATING MARGIN
24.07%
19.59% NET MARGIN
19.59%
15.39% ROE
15.39%
8.62% ROA
8.62%
10.82% ROIC
10.82%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Hologic, Inc.
image
3b3b2b2b2b2b1b1b500m500m00(500m)(500m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 790 M
Depreciation & Amortization 309 M
Capital Expenditures -140 M
Stock-Based Compensation 82.3 M
Change in Working Capital 84.1 M
Others 161 M
Free Cash Flow 1.14 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Hologic, Inc.
image
Wall Street analysts predict an average 1-year price target for HOLX of $80.4 , with forecasts ranging from a low of $65 to a high of $90 .
HOLX Lowest Price Target Wall Street Target
65 USD -4.29%
HOLX Average Price Target Wall Street Target
80.4 USD 18.39%
HOLX Highest Price Target Wall Street Target
90 USD 32.53%
Price
Max Price Target
Min Price Target
Average Price Target
909085858080757570706565606055555050Sep '24Sep '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 12
6. Ownership
Insider Ownership Hologic, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
1.9 M USD 1
9-12 MONTHS
8.3 M USD 4
Bought
301 K USD 1
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Why Hologic (HOLX) is a Top Value Stock for the Long-Term Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. zacks.com - 1 day ago
Interpreting Hologic (HOLX) International Revenue Trends Evaluate Hologic's (HOLX) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance. zacks.com - 1 day ago
Hologic, Inc. (HOLX) is Attracting Investor Attention: Here is What You Should Know Hologic (HOLX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock. zacks.com - 1 day ago
Hologic Stock Falls Despite Q3 Earnings and Revenue Beat, Margins Down HOLX posts better-than-expected Q3 results, but margin contraction and regional headwinds pressure investor sentiment. zacks.com - 5 days ago
Hologic (HOLX) Q3 Revenue Beats 1% Hologic (HOLX) Q3 Revenue Beats 1% fool.com - 5 days ago
Hologic, Inc. (HOLX) Q3 2025 Earnings Call Transcript Hologic, Inc. (NASDAQ:HOLX ) Q3 2025 Earnings Conference Call July 30, 2025 4:30 PM ET Company Participants Essex D. Mitchell - Chief Operating Officer Karleen M. seekingalpha.com - 5 days ago
Compared to Estimates, Hologic (HOLX) Q3 Earnings: A Look at Key Metrics The headline numbers for Hologic (HOLX) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. zacks.com - 5 days ago
Hologic (HOLX) Q3 Earnings and Revenues Beat Estimates Hologic (HOLX) came out with quarterly earnings of $1.08 per share, beating the Zacks Consensus Estimate of $1.05 per share. This compares to earnings of $1.06 per share a year ago. zacks.com - 5 days ago
Hologic raises annual profit forecast on diagnostic and surgical demand Medical equipment maker Hologic on Wednesday raised its annual profit forecast, anticipating strong demand for its molecular diagnostic devices and surgical products. reuters.com - 5 days ago
Hologic Focuses on Breast Health Turnaround This Year: Can It Deliver? HOLX eyes a Breast Health rebound in Q4, backed by leadership changes, new strategy and Endomag momentum. zacks.com - 1 week ago
Seeking Clues to Hologic (HOLX) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics Get a deeper insight into the potential performance of Hologic (HOLX) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics. zacks.com - 1 week ago
HOLX vs. EXAS: Which Cancer Diagnostics Stock Should You Retain Now? EXAS gains edge over HOLX as rising Cologuard adoption, new launches and bullish EPS trends boost investor appeal. zacks.com - 1 week ago
8. Profile Summary

Hologic, Inc. HOLX

image
COUNTRY US
INDUSTRY Medical - Instruments & Supplies
MARKET CAP $ 15.1 B
Dividend Yield 0.00%
Description Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.
Contact 250 Campus Drive, Marlborough, MA, 01752 https://www.hologic.com
IPO Date March 1, 1990
Employees 7063
Officers Ms. Monica Aguirre Berthelot Vice President & Chief of Staff Ms. Karleen M. Oberton CPA Chief Financial Officer Mr. Stephen P. MacMillan Chairman, Chief Executive Officer & President Ms. Anne Liddy General Counsel Mr. Paul Malenchini Chief Information Officer Dr. Jennifer M. Schneiders Ph.D. Division President of Diagnostic Solutions Mr. Jan Verstreken Group President of International Ms. Diana De Walt SPHR Senior Vice President of Global Human Resources Mr. Essex D. Mitchell Chief Operating Officer Mr. Michael J. Watts Corporate Vice President of Investor Relations